Lab Rats series: A Pune biotech startup’s new approach to vitiligo cure
Ahammune has advanced its first-in-class drug to solve vitiligo to mid-trials with a fraction of the cost of global peers. It’s not been an easy road, but the tide is turning.
Mint asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments